ArticleCancer research2020
Genomic and Epigenomic Landscaping Defines New Therapeutic Targets for Adenosquamous Carcinoma of the Pancreas.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Research advances and treatment perspectives of pancreatic adenosquamous carcinoma.Cellular oncology (Dordrecht, Netherlands) · 2023Pooled it
- Proteomic and immunocytochemical analyses of squamous components in two- and three-dimensional-cultured pancreatic ductal adenocarcinoma cell lines.Oncology letters · 2026Article
- Review
- [Research progress in clinical pathology and molecular mechanisms of pancreatic adenosquamous carcinoma].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2026Review
- Role of SMYD2 in gastrointestinal cancer progression (Review).Oncology letters · 2025Review
- Novel Uveal Melanoma Patient-Derived Organoid Models Recapitulate Human Disease to Support Translational Research.Investigative ophthalmology & visual science · 2024Article
- Single nucleus DNA sequencing of flow sorted archived frozen and formalin fixed paraffin embedded solid tumors.BMC genomics · 2024Article
- FGFR2-fusions define a clinically actionable molecular subset of pancreatic cancer.NPJ precision oncology · 2024Article
- Genomic landscape of diploid and aneuploid microsatellite stable early onset colorectal cancer.Scientific reports · 2024Article
- Epigenetic upregulation of MNAT1 by SMYD2 is linked to PI3K/AKT activation and tumorigenesis of pancreatic adenocarcinoma.Histology and histopathology · 2024Article
- Clinicopathological and molecular characteristics of colorectal adenosquamous carcinoma in an Asian population.BMC gastroenterology · 2024Article
- SETD2 loss in renal epithelial cells drives epithelial-to-mesenchymal transition in a TGF-β-independent manner.Molecular oncology · 2024Article
- A narrative review on rare types of pancreatic cancer: should they be treated as pancreatic ductal adenocarcinomas?Therapeutic advances in medical oncology · 2024Review
- KCNN1 promotes proliferation and metastasis of breast cancer via ERLIN2-mediated stabilization and K63-dependent ubiquitination of Cyclin B1.Carcinogenesis · 2023Article
- Loss of chromosome 9p21 is associated with a poor prognosis in adenosquamous carcinoma of the pancreas.Precision clinical medicine · 2023Article
- Single-cell mapping identifies MSICancer cell · 2023Article
- A super-enhancer-regulated RNA-binding protein cascade drives pancreatic cancer.Nature communications · 2023Article
- Genomic landscape and clinical features of rare subtypes of pancreatic cancer: analysis with the national database of Japan.Journal of gastroenterology · 2023Article
- Patient-derived xenograft models in cancer therapy: technologies and applications.Signal transduction and targeted therapy · 2023Review
- Palmitoyl transferases act as novel drug targets for pancreatic cancer.Journal of translational medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 7 institutions in 1 country.
Elizabeth LenkiewiczDivision of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic, Scottsdale, Arizona.
Smriti MalasiDivision of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic, Scottsdale, Arizona.
Tara L HogensonSchulze Center for Novel Therapeutics, Division of Oncology Research, Mayo Clinic, Rochester, Minnesota.
Luis F FloresSchulze Center for Novel Therapeutics, Division of Oncology Research, Mayo Clinic, Rochester, Minnesota.
Whitney BarhamSchulze Center for Novel Therapeutics, Division of Oncology Research, Mayo Clinic, Rochester, Minnesota.
William J PhillipsSchulze Center for Novel Therapeutics, Division of Oncology Research, Mayo Clinic, Rochester, Minnesota.
Alexander S RoeslerDivision of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic, Scottsdale, Arizona.ORCID 0000-0001-5768-1589
Kendall R ChambersDepartment of Pharmacology, University of California, San Diego School of Medicine, La Jolla, California.
Nirakar RajbhandariDepartment of Pharmacology, University of California, San Diego School of Medicine, La Jolla, California.ORCID 0000-0002-8756-0363
Akimasa HayashiThe David M. Rubenstein Center for Pancreatic Cancer Research, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York.
Corina E AntalGene Expression Laboratory, Salk Institute for Biological Studies, La Jolla, California.
Michael DownesGene Expression Laboratory, Salk Institute for Biological Studies, La Jolla, California.
Paul M GrandgenettFred and Pamela Buffett Cancer Center, Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, Nebraska.ORCID 0000-0002-6905-1805
Michael A HollingsworthFred and Pamela Buffett Cancer Center, Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, Nebraska.
Derek CridebringTranslational Genomics Research Institute, Phoenix, Arizona.
Yuning XiongDepartment of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota.
Jeong-Heon LeeDepartment of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota.
Zhenqing YeDepartment of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota.
Huihuang YanDepartment of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota.
Matthew C HernandezDepartment of Surgery, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0001-8084-9685
Jennifer L LeitingDepartment of Surgery, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-5784-7937
Ronald M EvansGene Expression Laboratory, Salk Institute for Biological Studies, La Jolla, California.
Tamas OrdogDepartment of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-3940-7284
Mark J TrutyDepartment of Surgery, Mayo Clinic, Rochester, Minnesota.
Mitesh J BoradDivision of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic, Scottsdale, Arizona.
Tannishtha ReyaDepartment of Pharmacology, University of California, San Diego School of Medicine, La Jolla, California.
Daniel D Von HoffTranslational Genomics Research Institute, Phoenix, Arizona.ORCID 0000-0003-4723-7681
Martin E Fernandez-ZapicoSchulze Center for Novel Therapeutics, Division of Oncology Research, Mayo Clinic, Rochester, Minnesota.
Michael T BarrettDivision of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic, Scottsdale, Arizona. barrett.michael@mayo.edu.
Mayo Clinic · USMayo Clinic in Arizona · USSalk Institute for Biological Studies · USUniversity of California San Diego · USTranslational Genomics Research Institute · USUniversity of Nebraska Medical Center · USMemorial Sloan Kettering Cancer Center · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MWomen's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Felicity Enders · 1985 to 2026
$151.3MViral Vector Core (VVC)P30CA014195 · NCI · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI Ye Zheng · 1985 to 2026
$82.8MYeast Genetics and Stress Response Genes-BiomedicalP42ES010337 · NIEHS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI TUKEY, ROBERT H · 2000 to 2022
$69.8MUNMC/EPPLEY CANCER CENTER SUPPORT GRANTP30CA036727 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Apar Kishor Ganti · 1985 to 2026
$55.0MTissue CoreP50CA127297 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI HOLLINGSWORTH, MICHAEL A. · 2008 to 2018
$17.1MHORMONAL REGULATION OF MAMMALIAN GENE EXPRESSIONR37DK057978 · NIDDK · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI EVANS, RONALD M · 2000 to 2019
$16.0MPancreatic Cancer Detection ConsortiumU01CA210240 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Michael A. Hollingsworth · 2017 to 2026
$12.9MMolecular strategies for early detection and targeting of cancerR35CA197699 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Tannishtha Reya · 2015 to 2026
$11.2MSpatial Regulation of Developmental Gene ExpressionR01HL105278 · NHLBI · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI EVANS, RONALD M · 2011 to 2019
$4.0MHormonal Regulation of Mammalian Gene ExpressionR01DK057978 · NIDDK · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI EVANS, RONALD M · 2021 to 2024
$2.6MCritical Resources Provided by UNMC Rapid Autopsy Program (RAP) Biorepository Stimulate Cancer ResearchR50CA211462 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Paul M Grandgenett · 2016 to 2026
$1.4MCancer Research UKNCI NIH HHS P30 CA008748NCI NIH HHS P30 CA014195NCI NIH HHS P30 CA015083NCI NIH HHS P30 CA036727NCI NIH HHS P50 CA127297NCI NIH HHS R35 CA197699NCI NIH HHS R50 CA211462NCI NIH HHS U01 CA210240NHLBI NIH HHS R01 HL105278NIDDK NIH HHS R01 DK057978NIDDK NIH HHS R37 DK057978NIEHS NIH HHS P42 ES010337
Abstract
Adenosquamous cancer of the pancreas (ASCP) is a subtype of pancreatic cancer that has a worse prognosis and greater metastatic potential than the more common pancreatic ductal adenocarcinoma (PDAC) subtype. To distinguish the genomic landscape of ASCP and identify actionable targets for this lethal cancer, we applied DNA content flow cytometry to a series of 15 tumor samples including five patient-derived xenografts (PDX). We interrogated purified sorted tumor fractions from these samples with whole-genome copy-number variant (CNV), whole-exome sequencing, and Assay for Transposase-Accessible Chromatin using sequencing (ATAC-seq) analyses. These identified a variety of somatic genomic lesions targeting chromatin regulators in ASCP genomes that were superimposed on well-characterized genomic lesions including mutations in
Indexed as
EpigenomeMutationProto-Oncogene Proteins p21(ras)Carcinoma, AdenosquamousCarcinoma, Pancreatic DuctalChromatinExome SequencingHumansOrganoidsPancreatic NeoplasmsReceptor, Fibroblast Growth Factor, Type 1Single-Cell AnalysisSmad4 ProteinChromatinFGFR1 protein, humanKRAS protein, humanProto-Oncogene Proteins p21(ras)Receptor, Fibroblast Growth Factor, Type 1Smad4 ProteinSMAD4 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.